4-Bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2- naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 12, 1996, Pages 1361-1366

  Glase, Shelly A ^a   Akunne, Hyacinth C ^a   Heffner, Thomas G ^a   Johnson, Stephen J ^a   Kesten, Suzanne R ^a   Mackenzie, Robert G ^a   Manley, Peter J ^a   Pugsley, Thomas A ^a   Wright, Jon L ^a   Wise, Lawrence D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMO 1 METHOXY N [2 (4 ARYL 1 PIPERAZINYL)ETHYL] 2 NAPHTHALENECARBOXAMIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; DOSE RESPONSE; DRUG SYNTHESIS; EXTRAPYRAMIDAL SYMPTOM; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC CORTEX; NONHUMAN; PSYCHOSIS; RAT; RECEPTOR AFFINITY; TARDIVE DYSKINESIA;

EID: 0029891127     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00231-4     Document Type: Article

References (12)

1. Sokoloff, T.; Giros, B.; Martres, M.-P.; Bouthenet, M.-L.; Schwartz, J.-C. Nature 1990, 347, 146.
2. Rognan, D.; Mann, A.; Wermuth, C.-G.; Martres, M.-P.; Giros, B.; Sokoloff, P.; Schwartz, J.-C.; Lecomte, J.-M.; Garrido, F. Eur. Pat. Appl. EP 539, 281, 1993, Chem. Abstr., 119, 139085a.
3. 1H NMR, IR, MS and microanalysis.
4. 3H]spiperone as previously described: Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; MacKenzie, R. G.; Shih, Y. H.; Damsma, G.; Wikström, H.; Whetzel, S. Z.; Georgic, L. M.; Cooke, L. W.; DeMattos, S. B.; Corbin, A. E.; Glase, S. A.; Wise, L. D.; Dijkstra, D.; Heffner, T.G. J. Pharmacol. Exp. Ther. 1995, 275, 1355.
5. Högberg, T. Drugs of the Future 1991, 16, 333.
6. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J.-C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A.; Wermuth, C. G. J. Pharmacol. Exp. Ther. 1995, 275, 1239.
7. Chio, C. L.; Lajiness, J. E.; Huff, R. M. Mol. Pharmacol, 1994, 45, 51.
8. This number represents the intrinsic activity of the compound. It is the maximal thymidine uptake of a test compound relative to the maximal thymidine uptake achieved by the full agonist quinpirole.
9. DOPA accumulation in rat brain after administration of compounds was used as a measure of effects on DA synthesis. This test was carried out according to methods described previously in reference 4.
10. Meller, E.; Bohmaker, K.; Goldstein, M.; Basham, D. A. Eur. J. Pharmacol. 1993, 249, R5.
11. (a) Strömbom, U. Catecholamine Receptor Agonists. Nauyn-Schmiedeberg's Arch. Pharmacol. 1976, 292, 167.
12. (b) Martin, G. E.; Bendesky, R. J. J. Pharmacol. Exp. Ther. 1984, 229, 706.